These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20449621)

  • 21. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
    Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Kryst J; Kawalec P; Pilc A
    PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
    AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
    Benson CA; van der Horst C; Lamarca A; Haas DW; McDonald CK; Steinhart CR; Rublein J; Quinn JB; Mondou E; Rousseau F;
    AIDS; 2004 Nov; 18(17):2269-76. PubMed ID: 15577539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.
    Ford N; Shubber Z; Hill A; Vitoria M; Doherty M; Mills EJ; Gray A
    PLoS One; 2013; 8(11):e79981. PubMed ID: 24244586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients.
    Di Biagio A; Ricci E; Viscoli C; Mesini A; Menzaghi B; Carenzi L; Orofino G; Parruti G; Martinelli C; Madeddu G; De Socio GV; Franzetti M; Quirino T; Bonfanti P;
    Curr HIV Res; 2013 Apr; 11(3):179-86. PubMed ID: 23432466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir: a review of its clinical potential in patients with HIV infection.
    Hervey PS; Perry CM
    Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
    Palacios R; Aguilar I; Hidalgo A; Santos J
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):965-71. PubMed ID: 17181413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
    Selinger-Leneman H; Matheron S; Mahamat A; Moreau J; Costagliola D; Abgrall S;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):206-11. PubMed ID: 17971717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.